The author reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Tam and colleagues¹ compare and contrast the findings of the aforementioned analysis to those of the PARTNER II randomized controlled trial. However, there are key differences in the populations studied in these 2 patient cohorts. The 5-year all-cause mortality in PARTNER II was 42.1% for surgical replacement and 46.0% for TAVR (hazard ratio, 1.09; 95% confidence interval, 0.95-1.25), yet in the aforementioned study, 5-year all-cause mortality was 16.1% for surgical replacement and 28.9% for TAVR ($P = .007$) with 100% complete 5-year follow-up in both studies. The average age in PARTNER II was 81.6 years and STS risk 5.8% compared with 80.5 years and 6% in the study by Muneretto and colleagues, making these differences in event rates difficult to reconcile. One explanation may be the greater average life expectancy in the countries in the study, ie, Italy (83.6 years), France (82.5 years), and Germany (81.2 years), compared with an average life expectancy of 78.9 years in the United States.⁵ In addition, the rate of previous coronary artery bypass grafting was 24.6% in PARTNER II and 4.3% in Muneretto and colleagues, signifying different patient populations, not directly comparable. There may be more to all-cause mortality in this age range than meets the eye.

Regardless of differences in patient cohorts, the overall 30-day mortality of 5.5% in the matched TAVR patients, along with 11-day mean length of stay, 1.7% tracheostomy rate, 7.9% vascular complication rate, are all quite high and likely due to the fact that only 66.2% of TAVRs were implanted via transfemoral approach for anatomic reasons.² Newer-generation TAVR devices have brought smaller sheath sizes enabling transfemoral approach for most patients, and technical expertise has improved, leading to much lower procedural complication rates in the most recent low-risk trials.

Context is critical in the interpretation of study results. Tam and colleagues have brought important additional insight into the discussion of the aforementioned results, and their thoughtful appraisal of the manuscript is undoubtedly appreciated by the readership of the *Journal*.

Truth be told, no design or methodology is perfect—and we, as surgeon–scientists, should always be cautious to accept “truths” or “certainty,” regardless of the old adage:

“a surgeon may be sometimes wrong, but never in doubt.”
As scientists, we must always be in doubt.

Charles M. Wojnarski, MD, MS
Division of Cardiovascular and Thoracic Surgery
Department of Surgery
Duke University Medical Center
Duke University
Durham, NC

References

1. Muneretto C, Solinas M, Folliguet T, Di Bartolomeo R, Repossini A, Laborde F, et al. Sutureless versus transcatheter aortic valves in elderly patients with aortic stenosis at intermediate risk: a multi-institutional study. *J Thorac Cardiovasc Surg.* 2022;163:925-35.e5.
2. Tam DY, Makhdom A, Cohen DJ. Unmeasured, unknown, and hidden: confounders are not always in plain sight. *J Thorac Cardiovasc Surg.* 2022;163:e237-8.
3. Senn S. Seven myths of randomisation in clinical trials. *Stat Med.* 2013;32:1439-50.
4. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. *N Engl J Med.* 2020;382:799-809.

<https://doi.org/10.1016/j.jtcvs.2020.09.094>

**REPLY FROM
AUTHORS: THE TRUTH
LIES:
TRANSCATHETER
AORTIC VALVE
IMPLANTATION
TRIALS ON PATIENTS
AT INTERMEDIATE
RISK**
Reply to the Editor:

We read with great interest the commentary of Tam and colleagues¹ and we appreciate the opportunity to discuss it. Our study² gave a new perspective about the comparison between surgery and transcatheter valve, analyzing the impact of the new technologies of sutureless valves on the outcome of patients with aortic stenosis with an intermediate- to high-risk profile. Tam and colleagues pointed out some criticism in terms of study design, concluding that propensity match observational studies cannot replace randomized controlled trials (RCTs).¹

Theoretically we agree about the role of RCTs, but we must point out that RCTs can themselves introduce several biases. The weakest point of any RCT may be the selection biases at the entry point of the study. Sponsored RCTs on transcatheter aortic valve implantation (TAVI) enroll only a small percentage (2%-8%) of patients treated either by TAVI or surgical aortic valve replacement (SAVR), leading to several selection biases. Specific risk factors for surgery (redo operation, patent internal mammary graft, chronic

Dr Muneretto reported consultant for LivaNova. Dr Di Bacco reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

obstructive pulmonary disease, etc) may be overexpressed in a “selected” study population, while unfavorable characteristics for TAVI (extent of calcification, the heart valve–vessel anatomy) may be underexpressed. Once the patient is enrolled in the study, subsequent randomization cannot reverse these selection biases, which affect the entire population. These biases may obviously deeply affect the study results and reliability of the conclusion. To date, important RCTs supported from transcatheter valves manufacturers, showed the noninferiority of TAVI when compared with surgery in patients at intermediate risk.^{3,4} Moreover, those trials reported an unusually high rate of strokes in the surgical population (30-day outcome: 5.6% SURTAVI, 6.1% PARTNER II). However, major international registries, which collect hundred thousands of patients (Society of Thoracic Surgeons, GARY Registries), report an incidence of stroke significantly lower in the same subset population (GARY Registry 1.0% stroke rate⁵). Furthermore, Brennan and colleagues⁶ analyzed data from the Transcatheter Therapy Registry and the Society of Thoracic Surgeons Registry (9464 propensity-matched patients with intermediate-high risk) and found that TAVR and SAVR resulted in an identical rate of stroke at 30 days (2.8%). The “uncommon” high incidence of stroke in the surgical group may have affected the reliability of SURTAVI and PARTNER II results.

Patients included in the surgical cohort of the aforementioned trials had several and specific risk factors such as previous coronary artery bypass grafting (PARTNER II 25%) and major associated surgical procedure (9.1%). The impact of these risk factors in the surgical group have not been adequately taken into consideration.³ Particularly, patients undergoing reoperation for SAVR with a patent mammary artery have a very high surgical risk (surgical mortality, range: 4%-16%). In addition, the high rate of patients with previous CABG enrolled in those trials does not reflect the standard worldwide population undergoing SAVR.^{5,7}

Finally, there are several warnings about the negative impact of permanent pacemaker implant on survival and new hospitalization rate.^{8,9} Only in the PARTNER I a dedicated analysis on this topic was performed,¹⁰ but there is a lack of data from PARTNER II and SURTAVI trials on patients at intermediate risk over 2 years’ follow-up.

The impact on the patient outcome of conduction disturbances and aortic regurgitation after TAVI needs to be better investigated at long term, before jumping to any conclusions.

Claudio Muneretto, MD

Lorenzo Di Bacco, MD

Division of Cardiac Surgery

University of Brescia Medical School

Brescia, Italy

References

1. Tam DY, Makhdom A, Cohen DJ. Unmeasured, unknown, and hidden: confounders are not always in plain sight. *J Thorac Cardiovasc Surg.* 2022;163:e237-8.
2. Muneretto C, Solinas M, Folliquet T, Di Bartolomeo R, Repossini A, Laborde F, et al. Sutureless versus transcatheter aortic valves in elderly patients with aortic stenosis at intermediate risk: a multi-institutional study. *J Thorac Cardiovasc Surg.* 2022;163:925-35.e5.
3. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med.* 2016;374:1609-20.
4. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med.* 2017;376:1321-31.
5. Werner N, Zahn R, Beckmann A, Bauer T, Bleiziffer S, Hamm CW, et al. Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis. *Circulation.* 2018;138:2611-23.
6. Brennan JM, Thomas L, Cohen DJ, Shahian D, Wang A, Mack MJ, et al. Transcatheter versus surgical aortic valve replacement: propensity-matched comparison. *J Am Coll Cardiol.* 2017;70:439-50.
7. Byrne JG, Karavas AN, Filsoufi F, Mihaljevic T, Aklog L, Adams DH, et al. Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. *Ann Thorac Surg.* 2002;73:779-84.
8. Mehaffey JH, Haywood NS, Hawkins RB, Kern JA, Teman NR, Kron IL, et al. Need for permanent pacemaker after surgical aortic valve replacement reduces long-term survival. *Ann Thorac Surg.* 2018;106:460-5.
9. Biner S, Michowitz Y, Leshem-Rubinow E, Topilsky Y, Ben-Assa E, Shimiaie J, et al. Hemodynamic impact and outcome of permanent pacemaker implantation following transcatheter aortic valve implantation. *Am J Cardiol.* 2014;113:132-7.
10. Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of Aortic Transcatheter Valves) trial and registry. *JACC Cardiovasc Interv.* 2015;8:60-9.

<https://doi.org/10.1016/j.jtcvs.2020.10.049>